July 13, 2011 -- For some men with early-stage prostate cancer, adding short-term hormone treatment to radiation therapy improves their chances of survival, according to a new study.
At the 10-year follow-up mark, 57% of those who got radiation alone survived, while 62% of those in the combination group were still alive, says William Shipley, MD, the Andres Soriano Professor of Radiation Oncology at Harvard Medical School.
The combination treatment made a difference not only in overall survival, but also in reducing deaths specifically from prostate cancer at the 10-year mark, he says. "In the ones with androgen deprivation therapy [hormone treatment], 4% died of prostate cancer," he tells WebMD. "With radiation alone, 8% did."
Men with intermediate risk of disease progression, as defined by several measures, benefited most from the combination treatment.
"If you have intermediate-risk prostate cancer and you are being treated with radiation, it will probably become standard treatment to have a short course of hormone treatment with that," Shipley says.
More than 240,000 U.S. men will be diagnosed with prostate cancer in 2011. Nine out of 10 will be diagnosed when the disease is in early stages, the researchers say.
The study is published in The New England Journal of Medicine.
Shipley and colleagues enrolled nearly 2,000 men with an age range of 47 to 91 who were judged to be at low, intermediate, or high risk of disease progression. The study began in 1994 and the median follow-up period was 9.1 years (half were followed longer, half less). All men had early-stage tumors when diagnosed.
The National Cancer Institute funded the study. It was conducted by the Radiation Therapy Oncology Group, which is administered by the American College of Radiology.
To assess the risk of disease progression, the researchers used several measures, including levels of PSA (prostate specific antigen, a protein made by the prostate gland and found in the blood), the Gleason score, and the stage of the tumor at diagnosis.
Most men were at intermediate risk.
The researchers assigned the men to the radiation-only group or the combination group. The combination group began taking the hormone therapy two months before the radiation began. They continued it during radiation, Shipley says. They took the hormone therapy for four months in all.